Search Results

Explore ground-breaking advancements in the treatment of movement disorders in this insightful interview with Prof. K. Ray Chaudhuri, who shares his key takeaways from the 10th Congress of the European Academy of Neurology meeting in Helsinki. He discusses promising new therapies, personalized care approaches, and significant research on the staging of Parkinson's. Additionally, Prof. Chaudhuri emphasizes the importance of holistic treatment, stepped-care strategies, remote management, and the potential of wearable technology in improving patient outcomes, bringing his wealth of knowledge and insights to touchNEUROLOGY

Parkinson’s disease (PD) is a complex neurodegenerative condition that predominantly affects older people, with a rising prevalence worldwide.1,2 There are many on-going challenges and unmet needs in PD: difficulties in making an accurate diagnosis (particularly in the early stages of the disease), troubling side effects associated with the available pharmacological treatments, a lack of effective disease-modifying therapies […]

Welcome to the latest edition of touchREVIEWS in Neurology. We are excited to present a collection of articles that showcase the latest advancements and diverse perspectives in neurological research and treatment. This issue features insightful reviews and editorials from esteemed experts, providing valuable insights into modern management strategies and novel therapeutic approaches for various neurological […]

Rescue medications are an important part of the treatment regimen for patients with intractable epilepsy, specifically those who experience seizure clusters or prolonged seizure episodes. Rescue medications are prescribed to end seizure activity quickly and effectively in order to prevent further seizure-related morbidities and prevent seizure recurrence. An ideal rescue medication is stable at room […]

Parkinson’s disease (PD) is characterized by prodromal and clinical stages; the clinical phase is characterized by a constellation of motor and non-motor symptoms (NMS).1 Despite the extensive discussions and publications of the clinical heterogeneity of PD,2 the precise heterogeneous pathological mechanisms, the natural history of PD and the progression pattern of many NMS remain unclear.3–7 There have also […]

Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder characterized by the degeneration of nigrostriatal dopaminergic neurons, with its incidence increasing globally.1 With disease progression, the benefit from medications shortens, and symptom control becomes strictly dependent on peripheral levodopa (L-dopa) levels, leading to the development of daily fluctuations of motor and non-motor symptoms severity and L-dopa-induced […]

Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]